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Watson et al S6.e2Background: Skin cancer is the most common form of cancer in the United States. Melanoma skin cancer
is particularly deadly; more than 8000 US residents die from it each year. Although recent reports suggest
that melanoma incidence rates have been increasing, these apparent increases could be caused by an
increase in reporting and/or screening, and by an actual increase in the occurrence of melanoma.Objective: In this report, we describe methods used in this supplement to assess the current burden of
melanoma in the United States using data from two federal cancer surveillance programs: the Centers for
Disease Control and Prevention (CDC) National Program of Cancer Registries and the National Cancer
Institute (NCI) Surveillance, Epidemiology, and End Results program. We also provide basic descriptive
epidemiologic data about melanoma in the United States.Methods: Cancer incidence data from population-based cancer registries that participate in the CDC
National Program of Cancer Registries and/or the NCI Surveillance, Epidemiology, and End Results
Program covering 78% of the US population for 2004 to 2006 were used.Results: Over 45 thousandmelanomas were diagnosed annually, with a rate of 19 cases per 100,000 persons.Limitations: Melanoma rates may vary because of differences in reporting, diagnosis, and screening.Conclusion: To our knowledge, the articles in this supplement constitute the first comprehensive
examination of the overall burden of melanoma in the United States based on data from a majority of the
US population. ( J Am Acad Dermatol 2011;65:S6.e1-12.)
Key words: cancer; epidemiology; melanoma; methods; public health; surveillance.Skin cancer is the most common form of cancer in
the United States.1 The two most common types of
skin cancerebasal cell and squamous cell carcino-
maseare highly curable. Melanoma occurs less fre-
quently but kills more people; more than 8000 US
residents die from melanoma each year.2 Although
melanoma incidence and mortality rates are highest
among adults age 75 years and older, melanoma is
among the top 10 most common cancers for those
aged 15 to 29 years.2,3
Exposure to ultraviolet (UV) light (from sunlight
or artificial sources, eg, tanning beds) is one of thethe Division of Cancer Prevention and Control, Centers for
isease Control and Prevention, Atlantaa; Cancer Data Registry of
ahob; Louisiana Tumor Registryc; Florida State Cancer Registryd;
niversity of Southern California/Keck School of Medicinee; and
issouri Cancer Registry and Department of Health Manage-
ent and Informatics, University of Missouri-Columbia.f
ication of this supplement to the JAAD was supported by the
ivision of Cancer Prevention and Control, Centers for Disease
ontrol and Prevention (CDC).
licts of interest: None declared.
opinions or views expressed in this supplement are those of
e authors and do not necessarily reflect the opinions,most preventable known risk factors for melanoma.4
Genetic factors, however, are also associated with
melanoma; people with lighter skin color, many
large nevi (moles), blue eye color, and red or blonde
hair color are at increased risk.5 The modifying role
of genetic factors may also explain why the associ-
ation between UVexposure and cancer risk is not as
clear-cut for melanoma as it is for basal and squa-
mous cell skin cancers.6 Among all major demo-
graphic groups in the United States, non-Hispanic
white males have the highest incidence rate of
melanoma.7recommendations, or official position of the journal editors or
the Centers for Disease Control and Prevention.
Preliminary findings from this study were presented at the 2010
Annual Conference of the North American Association of
Central Cancer Registries in Quebec City, Quebec, Canada,
June 19-25, 2010.
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dence rates have been increasing,8,9 whereas others
suggest that recent increases may be leveling off.10
Determining the extent to which melanoma inci-
dence rates have changed is difficult, in part because
many melanoma cases are diagnosed in nonhospital
settings and thus may be missed by central cancerCAPSULE SUMMARY
d We describe methods used in this
supplement to assess the current burden
of melanoma in the United States using
data from two federal cancer surveillance
programs.
d This article also provides a basic
overview of the descriptive
epidemiology of melanoma, using data
including more than 45 thousand
melanomas diagnosed each year and
covering up to 78% of the US
population.registries (CCRs), which tra-
ditionally have collected
most of their cases from hos-
pitals. Improvements in case
reporting, therefore, would
likely produce apparent in-
creases in melanoma inci-
dence rates, as would
increased screening (through
the recognition of previously
undiagnosed tumors).11-14
True increases in mela-
noma incidence rates are
thought to be related to in-
creases in unprotected UV
exposure.15,16 Variation in
melanoma rates by state can
be a result of variations in factors such as altitude,
latitude, and weather, all of which affect UV expo-
sure: among whites, the lowest rate of melanoma
during 2002 to 2006 (13/100,000) was in Alaska
where UVexposure is generally low, and the highest
rate (62/100,000) was in Hawaii, where UVexposure
is generally high.2,17 Because melanoma incidence
rates have increased while melanoma mortality has
remained relatively stable, some have proposed that
increases in incidence rates reflect better detection of
thinner tumors of unknown clinical significance
through screening.18,19 However, recent research
indicates that incidence rates of thicker melanomas
are also increasing in certain populations,12,20 and
that differences in diagnosis by histology have not
changed over time in ways that would be expected if
increased melanoma screening were solely respon-
sible for increases in melanoma incidence rates.12
Although difficulties in consistent histologic diagno-
sis of melanomas persist, histologic criteria have not
evolved sufficiently to account for the increasing
incidence in melanoma rates.
Until now, estimates of the burden of melanoma
in the United States have been most often based on
data from half of the US population or less.9,12 The
articles in this supplement, however, are based on
combined high-quality data from two federal sur-
veillance programs covering up to 78% of the US
population (Table I). They also provide important
new information on the burden of melanoma in the
United States, including the burden in populationsother than white, and information on the associa-
tion between UV exposure and melanoma rates by
geographic area and socioeconomic status, using
the most representative high-quality data available
to date in the United States.
METHODS
Data sources
Cancer registry and
mortality surveillance
systems. The articles in
this supplement are based
on cancer incidence data
from population-based can-
cer registries that participate
in the Centers for Disease
Control and Prevention
(CDC) National Program of
Cancer Registries (NPCR);
the National Cancer Institute
(NCI) Surveillance, Epide-
miology, and End Results
(SEER) Program; or
both.7,21,22 The SEERProgram, begun in 1973 as a result of the National
Cancer Act, initially collected and published cancer
incidence and survival data from population-based
cancer registries of 5 states and 4 metropolitan areas,
which covered approximately 10% of the US popu-
lation. Over time, the SEER Program has expanded
its coverage to include 9 states and 6 metropolitan
areas, approximately 26% of the US population.
Recognizing the need for more complete cancer
incidence data, Congress established the NPCR in
1992.23 NPCR now supports cancer registries in 45
states, the District of Columbia, Puerto Rico, and the
Pacific Island jurisdictions, which collectively cover
96% of the population (Fig 1). NPCR and SEER
provide dual support to 4 statewide cancer registries.
In addition, the SEER metropolitan-area and special-
population cancer registries report their incidence
data to both NCI and the NPCR statewide cancer
registries in their respective states. Together, NPCR
and SEER now collect cancer incidence data for the
entire US population. Both NPCR and SEER data are
collected and reported with use of standard data
items and uniform codes and procedures, as docu-
mented by the North American Association of
Central Cancer Registries (NAACCR).24 Registries in
each program also collect additional data items as
required by their funding agencies and may also
collect area- or state-specific data items. Reportable
skin cancers include in situ and invasive primary
melanomas and other rare cutaneous cancers but not
basal cell or squamous cell carcinomas of the skin,
Abbreviations used:
AI/AN: American Indian/Alaska Native
API: Asian/Pacific Islander
CCR: central cancer registry
CDC: Centers for Disease Control and
Prevention
NAACCR: North American Association of Central
Cancer Registries
NCI: National Cancer Institute
NPCR: National Program of Cancer Registries
SEER: Surveillance, Epidemiology, and End
Results
SS2K: SEER Summary Stage 2000
UV: ultraviolet
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Watson et al S6.e4except for those on the skin of the genital organs.25
Cancer cases are coded according to criteria in the
version of the International Classification of
DiseaseseOncology in use at the time of diagnosis.
Hospitals and other facilities that diagnose or treat
cancer collect and report cancer incidence data to
CCRs. All SEER registries and some NPCR-funded
registries also collect follow-up information used in
determining cancer survival statistics.26 Tumor, treat-
ment, and demographic information for cancer cases
are obtained primarily from medical records.
Although most cancer cases are still reported by
hospitals, data about these cases are increasingly
being obtained from nonhospital sources such as
pathology laboratories, radiation facilities, freestand-
ing surgery centers, long-term care facilities, and
physicians’ offices. Medical and demographic infor-
mation about a small percentage of these cases
(# 2% of all skin cancer cases, and\0.5% of mela-
noma cases) is obtained solely from death certifi-
cates. Before submitting data to CDC or the NCI, CCR
staff consolidate the data received from hospitals and
other facilities and use death certificates and other
sources of data to update information about the vital
status of patients whose cases are already in the
registry.27 Because the data submitted by the CCRs
are deidentified, they can be used in statistical and
analytic summaries and released in restricted data
sets for research.7,28
For deaths caused by cancer, we used cancer
mortality data obtained from death certificates con-
taining demographic information and cause of death
throughout the United States and coded using the
version of the International Classification of Disease
in use at the time of death. These data are reported to
state vital statistics offices and consolidated into a
national database by CDC through the National Vital
Statistics System.29 Underlying cause of cancer death
was coded to primary cancer site according to criteria
in the International Statistical Classification of
Disease, 10th Revision.30-32Databases used in this supplement. As noted
previously, the NPCR and SEER registries together
have covered 100% of the US population since 1998;
however, the cancer incidence data reported in this
supplement were only from registries that met the
following high-quality publication criteria for the
United States Cancer Statistics report for all years
from 1999 through 2006 or from 2004 through 2006
(depending on which set of years was used): case
ascertainment of at least 90% of expected cases as
estimated with use of methods developed by
NAACCR; greater than or equal to 97% of cases
passed a standard set of computerized edits; less than
or equal to 5% of cases reported by death certificate
only; less than or equal to 5% of cases with missing
information on race; less than or equal to 3% of cases
with missing information on sex; and less than or
equal to 3% of cases with missing information on
age.7,33 In addition, articles in this supplement also
excluded data from Illinois, New York, and Texas at
the request of those states.
Some of the articles in this supplement are based
on NPCR and SEER data from 2004 through 2006;
these data were from 46 registries that covered 77.6%
of the US population during those years (Table I): By
race/ethnicity, our study for 2004 to 2006 covers:
77.5% of whites (80.0% of non-Hispanic whites),
77.5% of blacks, 78.9% of Asian/Pacific Islanders
(API), 77.8% of American Indian/Alaska Natives (AI/
AN), and 65.1% of Hispanics. Regionally, 64.7% of
the population in the Northeast is covered, as are
72.3% of the Midwest, 78.7% of the South, and 91.3%
of the West. To examine more years of data or to
include larger case counts, some articles included in
this supplement use NPCR/SEER data from 1999
through 2006 drawn from 38 registries that covered
67.2% of the US population during those years.
Finally, because the SEER program has been in
existence since 1973, some articles examining treat-
ment, trends, and survival, which require more
detailed data over a longer period of time, were
limited to SEER data only. Fig 1 shows a map of areas
included in the NPCR and SEER programs.
Because melanoma is increasingly diagnosed and
treated in nonhospital settings, collecting these cases
poses challenges for CCRs that primarily collect most
of their cases from hospitals and may not have
resources to collect data from nonhospital settings.
To address concerns about underreporting of mela-
noma cases and to attempt to estimate the percent-
age of melanoma cases not identified by CCRs, we
evaluated invasive melanoma cases by state accord-
ing to several criteria, including the ratio of early-
stage to late-stage cases (because early-stage cases
are more likely to be diagnosed and treated in
Fig 1. States and metropolitan areas supported by Centers for Disease Control and
Prevention’s National Program of Cancer Registries (NPCR) program and National Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.
Table I. Data sets used in analyses reported in this supplement
1999-2006 2004-2006
38 Registries (covering 67.2% of US population) 46 Registries (covering 77.6% of US population)
Alaska Montana Alabama Missouri
California Nebraska Alaska Montana
Colorado Nevada Arkansas Nebraska
Connecticut New Hampshire California Nevada
Delaware New Jersey Colorado New Hampshire
Florida New Mexico Connecticut New Jersey
Georgia North Carolina Delaware New Mexico
Hawaii North Dakota Washington, DC North Carolina
Idaho Ohio Florida North Dakota
Indiana Oklahoma Georgia Ohio
Iowa Oregon Hawaii Oklahoma
Kansas Pennsylvania Idaho Oregon
Kentucky Rhode Island Indiana Pennsylvania
Louisiana South Carolina Iowa Rhode Island
Maine Utah Kansas South Carolina
Maryland Vermont Kentucky South Dakota
Massachusetts Washington Louisiana Tennessee
Michigan West Virginia Maine Utah
Minnesota Wyoming Maryland Vermont
Massachusetts Virginia
Michigan Washington
Minnesota West Virginia
Mississippi Wyoming
The 2004 to 2006 data set is used for current article and articles by Richards17 and Singh34 included in this supplement. The 1999 to 2006
data set is used for articles by Wu,35 Weir,36 and Lai37 included in this supplement. Articles in this supplement by Jemal,20 Balamurugan,38
and Pollack39 used Surveillance, Epidemiology, and End Results data only.
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Table II. Histology categories used in this
supplement
ICD-O-3 code ICD-O-3 histologic type
Percentage of all
melanomas in
2004-2006 data set
Superficial spreading melanoma
8743 Superficial spreading
melanoma
28.8%
Nodular melanoma
8721 Nodular melanoma 6.9%
Lentigo maligna melanoma
8742 Lentigo maligna melanoma 6.0%
Acral lentiginous melanoma
8744 Acral lentiginous
melanoma, malignant
1.0%
Melanoma NOS and other
8720-8790 with exception of above
numbers
57.2%
Subcategories of interest within NOS and other:
8745 Desmoplastic melanoma,
malignant
1.2%
8730 Amelanotic melanoma 0.4%
8746 Mucosal lentiginous
melanoma
0.0%
Melanomas in ‘‘Subcategories of interest’’ category are included in
‘‘Melanoma NOS and other’’ category. All cases used in histology
analyses are microscopically confirmed (99% of all cases in data set
for 2004-2006).
ICD-O-3, International Classification of DiseaseseOncology, Third
Edition; NOS, not otherwise specified.
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Watson et al S6.e6nonhospital settings and thus more likely to be
undercounted) and the ratio of incidence rates to
mortality (because death from melanoma is less
likely to bemissed, a lower than expectedmelanoma
incidence to mortality ratio suggests possible under-
reporting of cases). In addition, we performed sta-
tistical modeling similar to modeling used in other
articles included in this supplement to attempt to
determine whether variations in incidence by state
were a result of chance.17,34 States with several of
these indicators suggesting that melanoma cases may
have been missed were contacted for more informa-
tion regarding the completeness of their melanoma
data. Because factors other than unreported cases
may affect incidence rates, state-specific issues may
have affected incidence rates.
NPCR data for this supplement were reported to
CDC as of November 30, 2008, or January 31, 2009.
SEER data were reported to NCI as of November 2008
and were made available through the SEER Program
limited use data file released in April 2009.40 Data
from states that are supported by both NPCR and
SEER were reported to CDC as of November 30,
2008, or January 31, 2009.7
Variation by race (white, black, API, AI/AN) and
Hispanic ethnicity were examined extensively in this
supplement. NPCR- and SEER-funded registries ob-
tain information on the race andHispanic ethnicity of
patients with cancer from medical records, some-
times augmented by other sources (which are par-
ticularly needed in cases reported by physicians’
offices or pathology laboratories, the records
of which often do not contain race/ethnicity infor-
mation). Identification of Hispanic ethnicity for can-
cer cases was augmented by the NAACCR Hispanic
Identification Algorithm, a hierarchical algorithm
that uses race, birthplace, sex, maiden name, and
surname.41 CDC and other national partners have
established a strategy to improve identification of
cancer cases among AI/AN by linking with Indian
Health Service records. However, because Indian
Health Service covers only federally recognized
tribal areas, and because many AI/AN in urban areas
do not use Indian Health Service, cancer cases in AI/
AN populations are still likely to be underreported.
Cancer death data for 2004 to 2006 reported in this
supplement are based on records of deaths during
that period received as of April 2009. Because the
2003 revision of the US Standard Certificate of Death
allows medical examiners to indicate multiple races
for decedents, the racial code for multiracial dece-
dents was changed to indicate a single race (white,
black, AI/AN, or API).42
The population (denominator) data used to cal-
culate cancer incidence rate and mortality wereobtained from the 2000 US Census; SEER population
data for Hawaii were modified to improve the
accuracy of rates for the Hawaii population.43
Case definition and explanation of inclusion
and exclusion criteria
We included cancer cases coded as ‘‘melanoma
of the skin’’ (defined as having an International
Classification of DiseaseseOncology, Third Edition
site code of C44.0-C44.9 and histology codes of
8720-8790).44 Noncutaneous melanomas and mela-
nomas in genital areas (eg, vulva, penis, and peri-
anal areas) are not coded as ‘‘melanoma of the skin’’
and thus were not included in analyses in this
supplement. Authors limited analyses to invasive
melanomas unless otherwise specified. Melanoma
histology was examined by groups as described in
Table II; all analyses of histology were restricted to
melanoma cases confirmed by microscopic exami-
nation. In some studies included in this supplement,
all analyses were only of such microscopically
confirmed cases of melanoma. During 2004 through
2006, 99.1% of invasive melanoma cases in the
NPCR/SEER combined data set were microscopi-
cally confirmed. Cancer cases in which patients’ sex
Table III. Descriptive epidemiology of invasive
melanomas in United States, 2004 to 2006
Average
annual
count Rate 95% CI
All ages/races 45,566 19.22 (19.12-19.33)
Age at diagnosis, y
0-14 115 0.25 (0.22-0.27)
15-34 3819 6.11 (6.00-6.22)
35-64 22,929 24.27 (24.09-24.45)
$ 65 18,703 64.57 (64.03-65.10)
Sex
Male 25,782 24.05 (23.88-24.22)
Female 19,784 15.88 (15.75-16.00)
Race/ethnicity
White 43,168 21.55 (21.43-21.67)
White, Hispanic 779 4.71 (4.51-4.92)
White, non-Hispanic 42,389 23.27 (23.14-23.40)
Black 240 1.06 (0.98-1.14)
Asian/Pacific Islander 144 1.51 (1.36-1.66)
American Indian/Alaska
Native
84 4.58 (4.00-5.22)
Hispanic* 826 4.69 (4.50-4.90)
Site on body
Face and ears 5959 2.51 (2.47-2.55)
Scalp and neck 3317 1.39 (1.37-1.42)
Trunk 14,748 6.23 (6.17-6.29)
Upper extremities 11,156 4.70 (4.65-4.75)
Lower extremities 8080 3.43 (3.38-3.47)
NOS and other 2305 0.97 (0.95-0.99)
Histology
Superficial spreading
melanoma
13,002 5.50 (5.44-5.55)
Nodular melanoma 3126 1.31 (1.29-1.34)
Lentigo maligna
melanoma
2729 1.15 (1.12-1.17)
Acral lentiginous 453 0.19 (0.18-0.20)
Melanoma NOS and other 25,853 10.91 (10.83-10.99)
Stage
Localized 35,866 15.14 (15.05-15.23)
Regional 4106 1.73 (1.70-1.76)
Distant 1782 0.75 (0.73-0.77)
Unstaged 3812 1.61 (1.58-1.64)
Region
Northeast 8040 20.82 (20.56-21.09)
Midwest 8822 17.82 (17.61-18.04)
South 16,290 18.36 (18.21-8.53)
West 12,413 20.71 (20.52-0.92)
Data are from population-based cancer registries that participate
in National Program of Cancer Registries and/or Surveillance,
Epidemiology, and End Results Program and meet high-quality
data criteria (see Table I for list of registries). These registries cover
77.6% of population for 2004 to 2006. Rates are per 100,000
population and are age-adjusted to 2000 US standard population
(19 age groups; Census P25-1130).
CHSDA, Indian Health Service Contract Delivery Areas; CI, confidence
interval; NOS, not otherwise specified.
*Hispanic ethnicity is not mutually exclusive from race.
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analyses.
Some people have multiple cases of melanoma.
The melanoma rates and counts reported in this
supplement are based on the number of melanomas
in the population, not the number of people with
melanoma. Because people with multiple melano-
mas tend to be older, the age distribution of people
with cases of melanoma reported in this supplement
is older than if analyses had been based only on
patients’ first case of melanoma. Because of these
factors, caution should be exercised when interpret-
ing estimates of risk for melanoma presented in this
supplement.
Some articles in this supplement examine the
burden of in situ cancer (behavior code/2 in the
NPCR and SEER databases). Because many melano-
mas are diagnosed and treated in nonhospital set-
tings, they are more likely to be underreported than
other cancers, especially at early stages. In situ
melanomas are less likely to be reported than inva-
sive melanomas because they require less follow-up
treatment and because CCRs that receive reports on
paper from nonhospital facilities generally give pri-
ority to abstracting information about invasive
cases.45 For that reason, rates of in situ melanoma
cancers reported in this supplement should be
interpreted with caution.
Statistical analysis
Age-adjusted incidence and death rates were cal-
culated per 100,000 persons unless otherwise spec-
ified. Rateswere age-adjusted to the 2000US standard
population by the directmethod, using 19 age groups
(\1, 1-4, 5-9, 10-14, 15-19,.$ 85 years).46
Incidence and death rates and 95% confidence
intervals were calculated with SEER*Stat (version
6.5.2), a statistical software package developed by
the NCI.47 Confidence intervals were calculated with
the gamma method using the modification of Tiwari
et al.48 Rates were calculated by age, stage, and US
census region (Northeast, South, East, or West).49
Rates were also calculated for the following racial/
ethnic groupings: white (all, Hispanic, and non-
Hispanic), black, API, AI/AN, and Hispanic. The
‘‘Hispanic’’ category includes people of all races.
Other and unknown categories were not reported
separately because denominator information was
not available for these groups; thus, the total number
of melanoma cases among people in the racial/
ethnic categories for which rates were reported do
not equal the number of cases in the ‘‘all races
combined’’ category. Typically; CDC reports race
and Hispanic ethnicity separately; here, we com-
bined race and ethnicity categories to allow for
Fig 2. Invasive melanoma incidence rates among non-Hispanic whites, by state, 2004 to 2006.
Data are from population-based cancer registries that participate in National Program of Cancer
Registries and/or Surveillance, Epidemiology, and End Results Program and meet high-quality
data criteria (see Table I for list of registries). These registries cover 77.6% of population for
2004 to 2006. Rates are per 100,000 population and are age-adjusted to 2000 US standard
population (19 age groups; Census P25-1130).
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highest risk for melanoma.
The cancer staging system used by the NPCR
(SEER Summary Stage) changed during our years of
study. For cancers diagnosed in 1999 to 2000, stage
was coded according to SEER Summary Stage 1977;
for cancers diagnosed in 2001 to 2003, stage was
coded according to SEER Summary Stage 2000
(SS2K); and for 2004 to 2006, stage was coded
according to Collaborative Stage and then recoded
into Derived SS2K for 2004 to 2006.50 Melanoma
stage was not entirely consistent between SEER
Summary Stage 1977 and SS2K; compatibility with
Derived SS2K is unknown.37 Thus, most articles
examining stage using NPCR data used the most
recent coding scheme (Derived SS2K) and limited
analysis to diagnosis years 2004 to 2006.
RESULTS
Overview of the distribution of melanoma in
the United States
This ‘‘Results’’ section provides a general overview
of the distribution of melanoma incidence and mor-
tality in the United States. During 2004 to 2006,136,697 cases of melanoma were reported to the
registries previously described, covering 77.6% of the
population with a rate of 19.2 per 100,000 (Table III);
state rates ranged widely, from 11.9 to 72.4 (Fig 2).
Melanoma incidence rates had a strong positive
association with age; among people approximately
age 45 years or younger, rates were slightly higher
among females, but among those older, rates were
higher among men, with the difference generally
increasing with age (Fig 3). Melanoma rates varied
widely by race/ethnicity, with the rate among non-
Hispanic whites being 20-fold higher than that
among blacks. Overall, melanomas occurred most
commonly on the trunk and upper extremities (Table
III); however, although the trunk was the most
common location for melanomas among males, the
lower extremitieswere themost common location for
melanomas among females (Fig 4). Melanoma rates
by histology and stage are summarized in Table III.
The most common code for melanomas in our data
set (57%) was ‘‘melanoma not otherwise specified
and other,’’ (unspecified melanoma histology); ‘‘su-
perficial spreading melanoma’’ was the most com-
mon specified histologic type reported.
Fig 4. Incidence rates of invasive melanoma, by site on
body and sex, United States, 2004 to 2006. Data are from
population-based cancer registries that participate in Na-
tional Program of Cancer Registries and/or Surveillance,
Epidemiology, and End Results Program and meet high-
quality data criteria (see Table I for list of registries). These
registries cover 77.6% of population for 2004 to 2006. Rates
are per 100,000 population and are age-adjusted to 2000
US standard population (19 age groups; Census P25-1130).
NOS, Not otherwise specified.
Table IV. Melanoma mortality in United States,
2004 to 2006
Average
annual
count Rate 95% CI
All deaths 8246 2.71 (2.68-2.74)
Age at death, y
0-14 ; ; ;
15-34 241 0.30 (0.28-0.32)
35-64 3282 2.66 (2.61-2.71)
$ 65 4720 12.69 (12.48-12.91)
Sex
Male 5295 4.01 (3.95-4.07)
Female 2951 1.74 (1.71-1.78)
Race/ethnicity
White 8066 3.09 (3.05-3.13)
White, Hispanic 168 0.76 (0.69-0.83)
White, non-Hispanic 7891 3.31 (3.27-3.36)
Black 123 0.44 (0.40-0.49)
Asian/Pacific Islander 40 0.37 (0.30-0.44)
American Indian/
Alaska Native
17 0.80 (0.59-1.07)
Hispanic* 170 0.72 (0.66-0.79)
Region
Northeast 1616 2.68 (2.60-2.75)
Midwest 1855 2.68 (2.61-2.75)
South 3020 2.75 (2.69-2.81)
West 1754 2.71 (2.64-2.78)
Mortality data from National Center for Health Statistics, Centers for
Disease Control and Prevention. Rates are per 100,000 population
and are age-adjusted to 2000 US standard population (19 age
groups; Census P25-1130).
CI, Confidence interval; ;, cell was suppressed because there were
\16 cases during study period.
*Hispanic ethnicity is not mutually exclusive from race categories
(white, black, Asian/Pacific Islander, American Indian/Alaska
Native).
Fig 3. Age-specific incidence rates of invasive melanoma,
by sex, United States, 2004 to 2006. Data are from
population-based cancer registries that participate in Na-
tional Program of Cancer Registries and/or Surveillance,
Epidemiology, and End Results Program and meet high-
quality data criteria (see Table I for list of registries). These
registries cover 77.6% of population for 2004 to 2006. Rates
are per 100,000 population and are age-adjusted to 2000
US standard population (19 age groups; Census P25-1130).
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uted to melanoma, an average of 8246 deaths per
year (rate of 2.7 deaths/100,000 people) (Table IV).
The death rate was highest by age among those aged
65 years or older; higher among males than among
females (rates of 4.0 vs 1.7, respectively); and highest
by race/ethnicity among non-Hispanic whites.
DISCUSSION
Data limitations
This study has several limitations. As previously
discussed, differences in melanoma incidence ratesmay be a result of differences in the thoroughness
of case reporting, differences in screening and
diagnosis, or true differences in rates. Fig 5 shows
average melanoma rates for states with low, me-
dium, and high rates of melanoma, by early and late
stage. Rates of early-stage melanoma differed sig-
nificantly, whereas rates of late-stage melanoma
differed little by state. Although early-stage mela-
nomas are more likely to go unreported than late-
stage melanomas, differences in melanoma rates are
unlikely to be caused solely by differences in
reporting. Melanomas in people with darker skin
tone are less likely to be diagnosed at an early
stage, possibly because they may be less evident or
because people with darker skin are less concerned
about melanoma because they know that they are
at relatively low risk. State rates may also vary for
other reasons, including differences in socioeco-
nomic status of the population or differences in UV
Fig 5. Mean melanoma incidence rates, by stage, in 3
groups of US states, 2004 to 2006. Melanoma incidence
rates for states divided into 3 tertiles on basis of their rates
of early-stage melanoma. Although early-stage rates vary
widely, late-stage rates are similar. Data are from
population-based cancer registries that participate in Na-
tional Program of Cancer Registries and/or Surveillance,
Epidemiology, and End Results Program and meet high-
quality data criteria (see Table I for list of registries). These
registries covered 77.6% of population for 2004 to 2006.
Rates are per 100,000 population and are age-adjusted to
2000 US standard population (19 age groups; Census
P25-1130).
Fig 6. State example: Louisiana. Data from Louisiana
Tumor Registry. Rates are per 100,000 population and
are age-adjusted to 2000 US standard population (19 age
groups; Census P25-1130).
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for an example of how one state addressed rela-
tively low melanoma incidence rates. Also, because
we did not limit to only the first primary cancer in a
patient (82% of cases in our data set are first
primaries) but included all cases diagnosed in
persons with multiple subsequent cases of mela-
noma, some states may have high rates of early-
stage melanomas because of more patients with
multiple cases of melanoma.
Although some states and facilities require the
collection of data about tumor thickness, this infor-
mation is not consistently reported to NPCR at the
national level. Thus, articles in this supplement use
SEER data to examine tumor thickness. Tumor
thickness and depth of invasion have previously
been shown to be strongly associated with prognosis
and survival among patients with melanoma, as have
ulceration and mitosis.51,52 Data on tumor thickness
are expected to be included in NPCR data in the
future.
CONCLUSION
To our knowledge, the articles in this supplement
constitute the first comprehensive examination of
the overall burden of melanoma in the United States
based on data from a majority of the US population.
Given that current population-based cancer regis-
tries have covered 100% of the US population since
1998, we hope that with more thorough reporting of
melanoma cases to these registries, we will soon beable to monitor US melanoma rates and changes in
these rates with more accuracy and precision.33,53
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